Mary Clare Fraser compensation by year
STERIS Summary Compensation Table · all 3 fiscal years held| Component | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Salary | $434,180 | $447,934 | $461,615 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $462,531 | $466,140 | $609,542 |
| Option awards | $693,995 | $699,192 | $609,401 |
| Non-equity incentive | $246,122 | $263,954 | $377,902 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $11,701 | $13,780 | $15,262 |
| Total | $1,848,529 | $1,891,000 | $2,073,722 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: STERIS plc DEF 14A filed June 11, 2026, accession 0001193125-26-267599, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 2,505 | $553,931 | — |
| RSU | 2,313 | $511,474 | — |
| RSU | 2,040 | $451,105 | — |
| RSU | 2,028 | $448,452 | — |
| Option | 7,842 | — | $251.34 |
| Option | 2,306 | — | $250.06 |
| Option | 6,492 | — | $219.97 |
| Option | 8,904 | — | $267.66 |
Per the Outstanding Equity Awards at Fiscal Year-End table in STERIS plc's FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments STERIS discloses, by trigger · FY2026| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $464,738 | $0 | $18,818 | $861,458 |
| Change in control and involuntary termination | $929,476 | $1,972,492 | $18,818 | $3,298,688 |
| Change in control, no termination | $0 | $1,972,492 | $0 | $1,972,492 |
| Change in control and resignation for good reason | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in STERIS plc's FY2026 proxy. Estimates as the company printed them; a dash means it printed no figure.
STERIS’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Daniel Carestio | President and Chief Executive Officer | $11,508,522 |
| Karen Burton | Senior Vice President and Chief Financial Officer | $3,192,417 |
| J. Adam Zangerle | Senior Vice President, General Counsel and Company Secretary | $2,954,465 |
| Cary Majors | Senior Vice President and President, Healthcare | $2,450,424 |
| Michael Tokich | Senior Financial Advisor (Former Senior Vice President and Chief Financial Officer) | $2,229,993 |
| Mary Clare Fraser · this page | Senior Vice President and Chief Human Resources Officer | $2,073,722 |
The full STERIS compensation record
free company briefThis page is one person within STERIS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order STERIS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are STERIS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat